Agree Realty: Sichuan Kelun-Biotech’s Sac-TMT Gains Approval for Advanced Lung Cancer Treatment
- Sichuan Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) receives approval for advanced lung cancer treatment after TKI therapy.
- Sac-TMT improves patient outcomes compared to traditional platinum chemotherapy, marking a significant advancement in NSCLC care.
- The treatment's significance will be highlighted at the 2025 ESMO Congress, illustrating its impact on oncology.
Sichuan Kelun-Biotech Secures Milestone Approval for Breakthrough Lung Cancer Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. achieves a significant milestone with the National Medical Products Administration's (NMPA) approval of its antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT). This innovative treatment is specifically designed for adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have experienced disease progression following EGFR-tyrosine kinase inhibitor (TKI) therapy. This approval marks the third indication for sac-TMT, establishing it as a pioneering therapy with proven overall survival (OS) benefits over traditional platinum doublet chemotherapy in this challenging patient demographic.
Sac-TMT stands out as the only approved monotherapy targeting advanced EGFR-mutant NSCLC after TKI therapy or in combination with platinum chemotherapy. This distinction is crucial as it addresses a critical gap in treatment options for patients who are resistant to TKI therapies, offering a much-needed lifeline for a population that has limited choices. The Phase III OptiTROP-Lung04 study data reveals that sac-TMT, administered at a dose of 5 mg/kg every other week, significantly improves both progression-free survival (PFS) and OS when compared to the conventional platinum-based doublet chemotherapy. These findings are remarkable as they represent the first instance of an ADC demonstrating such benefits in a Phase III trial involving a Chinese population, highlighting the treatment's potential for broad-reaching impact.
The results of the OptiTROP-Lung04 study will be prominently featured as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Congress, further emphasizing the treatment's significance in the oncology landscape. This approval comes on the heels of sac-TMT's earlier clearance in March 2025, which permitted its use in patients who have failed both EGFR-TKI and platinum-based chemotherapy. As the landscape of NSCLC treatment evolves, sac-TMT's innovative approach is poised to redefine patient care and outcomes for those battling this aggressive form of cancer.
In addition to this groundbreaking approval, the ongoing advancements in ADC technology reflect a broader trend within the biopharmaceutical industry, underscoring the need for targeted therapies that address specific patient needs. As the medical community continues to explore the potential of such therapies, the focus remains on improving the quality of life and survival rates for patients facing difficult-to-treat cancers. The implications of these developments extend beyond individual treatments, signaling a paradigm shift in cancer therapeutics that could influence future research and investment strategies within the sector.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

